# A Study to Investigate the Efficacy and Safety Profile of GM-XANTHO [GM-XAN003] in Patients with Psoriasis

> **NCT06620692** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Xantho Biotechnology Co., LTD** · enrollment: 65 (estimated)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** 5% GM-XANTHO [GM-XAN003]
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06620692
- **Lead sponsor:** Xantho Biotechnology Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2024-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06620692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06620692, "A Study to Investigate the Efficacy and Safety Profile of GM-XANTHO [GM-XAN003] in Patients with Psoriasis". Retrieved via AI Analytics 2026-08-19 from https://api.ai-analytics.org/clinical/NCT06620692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*